T enecteplase offers a potential advance in acute thrombolysis for acute ischemic stroke with improved pharmacokinetics and pharmacodynamics over the current standard-of-care alteplase. The Australian-TNK (low-dose tenecteplase versus standard-dose alteplase for acute ischemic stroke) phase IIb trial found that patients randomized to tenecteplase 0.25 mg/kg had double the rate of recanalization, leading to double the rate of patients living with minimal disability at day 90, compared with patients randomized to alteplase 0.9 mg/kg. 1, 2 In this trial, baseline computed tomography (CT) perfusion (CTP) was used to identify a treatment-responsive patient group with a visible penumbral pattern. 3 Penumbral imaging has been the focus of much research and is a clinically available advanced imaging patient assessment used to identify salvageable cerebral tissue and to demarcate this tissue from infarcted brain to measure a ratio of salvageable brain to infarcted brain called mismatch. The refined concept of target mismatch was tested in the DEFUSE 2 study (Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2), 4 which showed that patients with target mismatch had an 8.8-times greater chance of a better 90-day outcome with reperfusion compared with patients without target mismatch. The large treatment effect is presumably due to the preferential treatment of patients who have a substantial volume of brain to salvage, which would otherwise infarct and cause substantial long-term disability. Automation of baseline imaging processing was not available during the Australian-TNK study, and investigators were required to visually identify penumbra on baseline perfusion imaging, which led to some enrolled patients not meeting the target mismatch criteria as a result of clinician judgment error. Therefore, reanalysis with automated imaging postprocessing may be of value.
The ATTEST phase IIb trial (Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis) acquired similar baseline multimodal CT imaging for use as an outcome biomarker. However, to explore a less selected but more generalizable patient population, ATTEST did not require target mismatch as an inclusion criterion and did not replicate the Australian-TNK results. 5 We sought to pool clinical and perfusion imaging from 2 studies to compare the treatment effect of tenecteplase versus alteplase on clinical and imaging biomarkers of outcomes. We hypothesized that patients classified as having target mismatch would be more likely to have a superior treatment effect of tenecteplase over alteplase on clinical outcomes.
METHODS

Trials Description
The Australia-TNK and ATTEST trials were prospective, randomized, open, blinded end-point studies comparing the efficacy and safety of alteplase and tenecteplase in thrombolysis-eligible patients with acute ischemic stroke, with clinical and imaging biomarkers used for outcome evaluation. The Australia-TNK study recruited from 3 sites, and ATTEST was a single-center study. For both studies, patients were eligible if they had a clinically diagnosed supratentorial acute ischemic stroke with a measurable deficit on the National Institutes of Health Stroke Scale (NIHSS; score range, 0-42 with 0 indicating no symptoms and 42 indicating death), were ≥18 years of age, were living independently before the stroke, and were considered eligible for intravenous thrombolysis according to clinical guidelines. Both studies included patients >80 years of age. Both trials excluded patients with major early ischemic change on noncontrast CT (NCCT) defined as hyperdense middle cerebral artery/basilar artery sign, sulcal effacement, basal ganglia/ subcortical hypodensity, and loss of cortical gray-white matter differentiation. In ATTEST, patients had to present to the hospital within 4.5 hours of symptom onset, and in the Australian study, patients were included up to 6 hours after onset. In ATTEST, patients were randomized to either tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg treatment on a 1:1 basis. The Australia-TNK trial randomized patients to alteplase 0.9 mg/ kg or 1 of 2 doses of tenecteplase (0.1 or 0.25 mg/kg) on a 1:1:1 basis. This analysis pooled trial data on patients receiving the 0.25-mg/kg dose of tenecteplase or 0.9 mg/kg alteplase and excluded the 0.1-mg/kg group from analysis because of the lack of a dose comparator. A key inclusion criteria difference between the 2 trials was that Australia-TNK patients were required to have visible CTP mismatch (by qualitative assessment) and an intracranial vessel occlusion on CT angiography (CTA; excluding internal carotid artery occlusions) before randomization. ATTEST used standard-of-care NCCT thrombolysis eligibility, obtaining advanced CT imaging (CTP and CTA) after randomization but before therapy initiation. Initial stroke severity evaluated by NIHSS score was measured in all patients immediately and at 24 hours, and resulting disability was assessed with the modified Rankin Scale (mRS; score range, 0-6 with 0 being no disability and 6 being death) at 90 days. These studies were approved by the local institutional review committees, and each participant provided written informed consent.
Imaging Acquisition
For both studies, baseline CT imaging included NCCT, CTP, and CTA with 64-slice scanners with 120-mm coverage. NCCT was followed by perfusion CT, comprising two 60-second
Clinical Perspective
What Is New?
• Tenecteplase for ischemic stroke may result in improved patient outcomes compared with current standard-of-care alteplase; however, clinical trials show varying results.
What Are the Clinical Implications?
• We have shown that patients with mismatch as identified on baseline computed tomography perfusion imaging show significantly improved clinical outcomes when treated with tenecteplase compared with alteplase.
series with 40 mL contrast agent (Ultravist 370; Bayer HealthCare, Berlin, Germany) injected at 6 mL/s followed by 30 mL saline at 6 mL/s. CTA was performed after CTP with acquisition from the aortic arch to the top of the lateral ventricles 6 with a second contrast injection of 40 mL contrast (Ultravist 370) injected at 6 mL/s followed by 30 mL saline at 6 mL/s. Follow-up NCCT and CTA were performed with the same acquisition as the baseline scan in ATTEST and at 24 to 48 hours after thrombolysis. Follow-up imaging for the Australia-TNK study was on 1.5-T magnetic resonance imaging scanners (Siemens Avanto). Magnetic resonance imaging sequences included an axial gradient-echo T2*-weighted series, diffusion-weighted imaging, magnetic resonance angiography, perfusion-weighted imaging, and flow-attenuated inversion recovery.
Pooled Imaging Analysis
CTP imaging is able to identify both critically ischemic tissue and established infarction using thresholds of ischemia. The optimal measures have been validated against magnetic resonance imaging. The delay in the time it takes for blood to reach a particular region is used to identify ischemia (delay time [DT] ), and the severity in the reduction of blood flow is used to identify infarction (cerebral blood flow). Individual patient imaging was centrally analyzed with commercial software (MIStar, Melbourne, Australia) by investigators blinded to clinical status and treatment allocation. Image analysis was performed in Newcastle, Australia, by 2 stroke neurologists and a clinical scientist. All perfusion imaging was processed with the singular value deconvolution algorithm with delay and dispersion correction 7 to generate maps of cerebral blood flow, cerebral blood volume, mean transit time, and DT. Next, validated thresholds to measure the baseline penumbra and ischemic core volume were applied. The perfusion lesion was defined as tissue with a DT of >3 seconds and the ischemic core as tissue within the perfusion lesion (DT >3 seconds) but with a cerebral blood flow of <30% of baseline flow as determined from singular value deconvolution output. 8 The penumbra was defined as tissue within the perfusion lesion but not in the ischemic core (DT >3 seconds, cerebral blood flow >30%). 9, 10 The mismatch ratio was determined as the ratio of the perfusion lesion volume (DT >3 seconds) to the volume of the ischemic core (DT >3 seconds, cerebral blood flow <30%). Severe hypoperfusion was defined as DT >8 seconds.
We then classified patients as having target mismatch or no target mismatch on the basis of whether they met the DEFUSE 2 target mismatch criteria (absolute mismatch volume >15 mL, mismatch ratio >1.8, baseline ischemic core <70 mL, and volume of severely hypoperfused tissue <100 mL). We used DT >8 seconds to define severely hypoperfused tissue. Penumbral salvage was defined as the proportion of baseline penumbra that did not progress to infarction on 24-to 48-hour NCCT (ATTEST) or 24-hour diffusion-weighted imaging (Australian study). Infarct growth was defined as the growth from baseline CTP ischemic core (DT >3 seconds, cerebral blood flow <30%) volume to 24-to 48-hour NCCT or 24-hour diffusion-weighted imaging.
All baseline CTAs were assessed centrally for occlusion status and site of occlusion. The studies originally used slightly different methods to define baseline vessel occlusion and vessel recanalization at 24 to 48 hours. For the pooled analysis, we classified baseline occlusion status as normal, partial (using dynamic CTP source images to confirm/exclude residual antegrade flow by assessing whether distal arteries branches filled with contrast before the divisions), or complete occlusion (no antegrade flow). 11 Patients with normal baseline CTA were not included in the recanalization assessments.
Brain hemorrhage outcomes were the occurrence of any parenchymal hematoma (PH) and large PH, as defined by ECASS-2 (Second European-Australasian Acute Stroke Study). We defined symptomatic intracerebral hemorrhage according to the Safe Implementation of Thrombolysis in Stroke Monitoring Study 12 as large PH accompanied by neurological deterioration by ≥4 points on the NIHSS.
Statistical Analysis
Statistical analysis was performed with Stata version 14. First, in a post hoc analysis, we compared between trials the baseline clinical and reprocessed imaging of Australia-TNK and ATTEST using Wilcoxon rank-sum tests and Fisher exact tests when appropriate. We then pooled the per-protocol patient information from the 2 studies for tenecteplase 0.25 mg/kg and alteplase 0.9 mg/kg to compare the betweengroup treatment effect of tenecteplase compared with alteplase on the clinical scores of the NIHSS and mRS, as well as reprocessed imaging outcomes, using Wilcoxon rank-sum tests and Fisher exact tests. Where proportions were concerned, we fitted a logistic regression model to calculate the odds ratio (OR; mRS score 0-1 and ordinal mRS) and fitted a separate logistic regression model with target mismatch as an interaction term. The primary focus of the analysis was to determine patient treatment responsiveness on the mRS to tenecteplase compared with alteplase in the pooled analysis or in the target mismatch subgroups. Imaging outcomes were rates of brain hemorrhage (any PH, large PH, and symptomatic intracerebral hemorrhage), penumbral salvage, infarct growth, and recanalization.
Next, patients were classified according to the target mismatch criteria, and the treatment effect of tenecteplase versus alteplase was compared for target mismatch and nontarget mismatch patients separately as a subgroup analysis. We sought to compare the treatment effect of tenecteplase compared with alteplase in patients with target mismatch on the clinical scores of the NIHSS and mRS and reprocessed imaging outcomes with Wilcoxon rank-sum tests and Fisher exact tests, or where proportions were concerned, we fitted a logistic regression model to calculate the OR (dichotomous mRS score 0-1 and ordinal mRS). For dichotomous outcomes, the OR represents the increase in likelihood of having a good outcome, whereas for an ordinal outcome, the OR represents the likelihood of not having a worse outcome with tenecteplase.
Lastly, we examined the number and percentage of patients with an mRS score of 0 to 1 outcome by treatment group and stratified those who met the target mismatch criteria and those who did not. To test whether the ORs of excellent outcome for target mismatch versus non-target mismatch were statistically significantly different for each group, we fitted a logistic regression model to determine whether there was a statistically significant interaction for treatment on the target mismatch criteria.
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RESULTS
The 96 patients from the ATTEST per-protocol analysis and 50 from the Australian-TNK study were pooled for a combined analysis of 146 patients who were randomized to either 0.25 mg/kg tenecteplase or 0.9 mg/kg alteplase. Seventy-one patients received alteplase and 74 received tenecteplase. The Australian study had a higher median baseline NIHSS score (15 for Australian-TNK versus 12 for ATTEST; P=0.008) and shorter onset-to-treatment time (168 minutes for Australian-TNK versus 199 minutes for ATTEST; P=0.002; Table 1 ). There were considerable differences in baseline imaging characteristics (Table 1) , with the Australian study having larger baseline perfusion lesions, greater mismatch, and a larger proportion of patients with any baseline vessel occlusion. Table 3 ). In a logistic regression model using target mismatch status as an interaction term, there was also no significant improvement in 3-month outcome in patients treated with tenecteplase (mRS score 0-1: OR, 1.77; 95% CI, 0.89-3.51; P=0.076; interaction P=0.385). The tenecteplase-treated patients showed more favorable imaging outcomes, with less infarct growth (tenecteplase, 1.2 mL; alteplase, 18.3 mL; P<0.001) and greater vessel recanalization (tenecteplase, 87%; alteplase, 37%; P<0.001; Table 3 ). PH also tended to be lower with tenecteplase (3% for tenecteplase versus 14% for alteplase; P=0.02), but the rates of symptomatic intracerebral hemorrhage were not significantly different (1 tenecteplase patients versus 5 alteplase patients; P=0.12; Table 4 ).
Pooled Analysis (Mismatch Patients): Tenecteplase Versus Alteplase
Seventy-four of the 146 patients fulfilled target mismatch criteria, with 33 receiving tenecteplase and 35 receiving alteplase and a larger proportion of the Australian-TNK study population (82%) fulfilling target mismatch criteria compared with ATTEST (34%; P<0.001). Target mismatch patients treated with tenecteplase had greater early improvement (median NI-HSS change: tenecteplase, 6; alteplase, 1; P<0.001) and less PH (0% for tenecteplase versus 21% for alteplase; P=0.003) and symptomatic intracerebral hemorrhage (0% for tenecteplase 0% versus 12% for alteplase; P=0.04). Patients with target mismatch had significantly higher odds of achieving an mRS score of 0 to 1 (mRS score 0-1: OR, 2.33; 95% CI, 1.13-5.94; P=0.032; Table 2 ) and were less likely to have a poor outcome (ordinal: OR, 0.31; 95% CI, 0.12-0.74; P=0.009). Target mismatch patients treated with tenecteplase also had higher recanalization rates (90% for tenecteplase versus 33% for alteplase; P<0.001) and less infarct growth (1.2 mL for tenecteplase versus 18.3 mL for alteplase; P<0.001; Table 4 and Table  I in the online-only Data Supplement).
Pooled Analysis: Interaction Between Treatment and Presence of Mismatch on 90-Day Outcome
Patients not fulfilling target mismatch criteria did not benefit from tenecteplase treatment (mRS score 0-1: 
DISCUSSION
In a post hoc analysis of 2 randomized trials, we have identified that treatment with tenecteplase is associated with fewer PH events, greater early clinical improvement, reduced infarct growth, and higher vessel recana- ATTEST indicates Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis; CI, confidence interval; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and OR, odds ratio. A low ordinal mRS is used to indicate that tenecteplase-treated patients were less likely to have a high mRS score at 90 days compared with alteplase-treated patients. lization rates. However, in the overall trial population, there was no improvement in 90-day clinical outcome. Importantly, however, in the subgroup of patients with target mismatch, there was a significantly better 90-day outcome with tenecteplase treatment compared with alteplase. The results of this pooled analysis provide additional evidence that tenecteplase is potentially a safer, more effective thrombolytic agent than alteplase. The entire pooled group had higher recanalization rates with tenecteplase, approaching rates seen with the recent endovascular trials [13] [14] [15] [16] that carried over into improved early and 90-day clinical outcomes in the patients with target mismatch. The greater early clinical improvement seen in the entire pooled group was likely driven by the target mismatch patients because no differences in clinical outcomes were seen between tenecteplase and alteplase in the subgroup without target mismatch. 17 There were significant baseline clinical and multimodal CT imaging characteristic differences between the 2 pooled trials, reflecting crucial differences in trial imaging eligibility criteria. The Australian-TNK study included a relatively homogeneous patient group based on multimodal CT imaging selection. Consequently, the greater reperfusion and recanalization seen with tenecteplase resulting in improved early and 90-day functional outcomes in patients with target mismatch were exaggerated and translated into better imaging and clinical outcomes than seen in ATTEST. A key limitation, however, of the enriched population selection approach is generalizability, with ATTEST addressing this issue by including a broader stroke population. This is most apparent in that ATTEST screened 157 thrombolysis-eligible patients and the Australian-TNK study screened 604 thrombolysiseligible patients, with 341 excluded because of imaging results such as no target mismatch or the presence of a large established infarct core. However, the present analysis demonstrates that the broad strategy used in ATTEST that does not require imaging criteria can lead to the inclusion of patients with little to gain from intravenous tenecteplase, as seen in the patients not fulfilling target mismatch criteria analysis in which there was no clinical benefit from treatment with tenecteplase over alteplase in our limited sample. To that end, when target mismatch was added as an interaction term to the whole pooled population analysis, there was no change in outcomes, likely because our sample was underpowered to show such an interaction. In a heterogeneous condition such as stroke, broad inclusion may incur a large cost to trial power and may risk overwhelming a potential major treatment effect in a particular subgroup who have the relevant biological target (eg, target mismatch patients) 18, 19 and thus require large pooled analyses such as this to demonstrate any clinical benefit.
The higher brain hemorrhage rate in the alteplase-treated patients is of particular interest given that it appears to be driven by hemorrhage occurring mainly in the target mismatch patients. The mechanism is not well understood, 20 but prior alteplase studies indicate that late recanalization is associated with higher rates of hemorrhage. 21 This may make tenecteplase treatment a preferential treatment option for patients at high risk of hemorrhage such as the elderly or those who have recently undergone surgery. In the present study, we saw greater infarct growth in the target mismatch alteplase group than with tenecteplase, possibly reflecting less effective (and later) recanalization and reperfusion with alteplase. Thus, in the alteplase target mismatch patients, the increased bleeding may have occurred as a result of late reperfusion into tissue, which was originally penumbral but had progressed to infarction by the time of reperfusion. The rates of brain hemorrhage were much lower in the non-target mismatch patients, likely reflecting smaller ischemic lesions in this group. Additionally, alteplase is known to interact significantly with the blood-brain barrier, which is thought to further exacerbate the risk of bleeding, whereas tenecteplase has much less blood-brain barrier interaction and may lead to reduced risk of hemorrhagic transformation and PH. 22 Limitations of this study include a relatively small data set from 2 clinical phase II trials that were not designed to test clinical benefit and with significant heterogeneity in design and imaging outcome measurement. Thus, these results are hypothesis generating. In addition, the rates of transient ischemic attack, stroke reoccurrence, and cardiovascular accident and death beyond 90 days cannot be assessed in the present study because of the limited reporting time frame. A prospective, randomized, clinical trial of patients meeting target mismatch criteria is required to confirm the findings of this study.
The potential for higher rates of early recanalization, with lower PH risk and improved early and 90-day outcomes compared with alteplase, strongly supports large phase III trials of tenecteplase for stroke thrombolysis. Improvements in thrombolytic drug safety and efficacy remain critically important even in the setting of the recent positive endovascular treatment trials because such treatment was adjunctive to thrombolytic therapy and endovascular treatment is likely to remain an option for a minority of patients. Complementary phase III trial designs for ongoing studies will yield important information on a potentially safer, more effective intravenous thrombolytic agent, tenecteplase, and more evidence to support the generalizability of multimodal CT selection of patients for reperfusion therapy.
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